Journal Mobile Options
Table of Contents
Vol. 220, No. 2, 2010
Issue release date: March 2010

Clinicopathological Study of 13 Cases of Squamous Cell Carcinoma Complicating Hidradenitis Suppurativa

Lavogiez C. · Delaporte E. · Darras-Vercambre S. · Martin De Lassalle E. · Castillo C. · Mirabel X. · Laurent F. · Patenotre P. · Gheit T. · Talmant J.C. · Beylot-Barry M. · Martinot V. · Piette F. · Aubin F. · Mortier L.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: To the best of our knowledge, only 52 cases of squamous cell carcinoma (SCC) complicating hidradenitis suppurativa (HS) have been reported since 1958. We describe 13 new cases. Methods: We propose a clinical and histological analysis of our cases. We include these results in a review of previously reported cases to analyze a total of 65 patients. In our series of 13 cases, we also investigate the presence of human papillomavirus (HPV) in tumor samples, by polymerase chain reaction (PCR) on paraffin-embedded material. Results: Malignant transformation affects mainly men with a long-term history of genitoanal HS. Although our cases were 7 well-differentiated carcinomas and 6 verrucous carcinomas, lymphatic and visceral metastasis occurred in 2 and 3 cases, respectively. With PCR, we demonstrated presence of HPV in genitoanal tumoral lesions, principally HPV-16. Conclusion: SCC complicating HS evolves poorly, despite a good histological prognosis. Our results sustain the implication of HPV in the malignant transformation of HS.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Hidradenitis suppurativa foundation 7895 via Belfiore No, San Diego, California 92129. www.hs.foundation.org.
  2. Slade DEM, Powell BW, Mortimer PS: Hidradenitis suppurativa: pathogenesis and management. Br J Plast Surg 2003;56:451–461.
  3. Jemec GB, Heidenheim M, Nielsen NH: The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996;35:191–194.
  4. Revuz JE, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al: Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008;59:596–601.
  5. König A, Lehmann C, Rompel R, Happle R: Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology 1999;198:261–264.
  6. Mortimer PS, Luniss PJ: Hidradenitis suppurativa. J R Soc Med 2000;93:420–422.
  7. Lapins J, Jarstrand C, Emtestam L: Coagulase-negative staphylococci are the most common bacteria found in cultures from the deep portions of hidradenitis suppurativa lesions, as obtained by carbon dioxide laser surgery. Br J Dermatol 1999;140:90–95.
  8. Jemec GB, Thomsen BM, Hansen U: The homogeneity of hidradenitis suppurativa lesions: a histological study of intra-individual variation. APMIS 2007;105:378–383.
  9. Vossler JL, Forbes BA, Adelson MD: Evaluation of the polymerase chain reaction for the detection of human papillomavirus from urine. J Med Virol 1995;45:354–360.
  10. Gheit T, Landi S, Gemignani F, Snijders PJ, Vaccarella S, Franceschi S, Canzian F, Tommasino M: Development of a sensitive and specific assay combining multiplex PCR and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types. J Clin Microbiol 2006;44:2025–2031.
  11. Gheit T, Billoud G, de Koning MN, Gemignani F, Forslund O, Sylla BS, Vaccarella S, Franceschi S, Landi S, Quint WG, Canzian F, Tommasino M: Development of a sensitive and specific multiplex PCR method combined with DNA microarray primer extension to detect betapapillomavirus types. J Clin Microbiol 2007;45:2537–2544.
  12. Cazzaniga M, Gheit T, Casadio C, Khan N, Macis D, Valenti F, Miller MJ, Sylla BS, Akiba S, Bonanni B, Decensi A, Veronesi U, Tommasino M: Analysis of the presence of cutaneous and mucosal papillomavirus types in ductal lavage fluid, milk and colostrum to evaluate its role in breast carcinogenesis. Breast Cancer Res Treat 2009;114:599–605.
  13. Von der Werth JM, Williams HC: The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2000;14:389–392.
  14. Anderson MJ, Dockerty MB: Perianal hidradenitis suppurativa. Dis Colon Rectum 1958;1:23–31.
  15. Pérez-Diaz D, Calvo-Serrano M, Martinez-Hijosa E: Squamous cell carcinoma arising in hidradenitis suppurativa. J Dermatol Surg Oncol 1995;10:225–228.
  16. Crickx B, Dontenwille MN, Grossin M, Banzet P, Belaich S: Carcinome épidermoïde sur maladie de Verneuil. Ann Dermatol Vénéréol 1983;110:705.
  17. Brown MD, Zachary CB, Grekin RC, Swanson NA: Genital tumors: their management by micrographic surgery. J Am Acad Dermatol 1988;18:115–122.
  18. Welsh DA, Powers JS: Elevated parathyroid hormone-related protein and hypercalcemia in a patient with cutaneous squamous cell carcinoma complicating hidradenitis suppurativa. South Med J 1993;86:1403–1404.
  19. Shukla VK, Hughes LE: A case of squamous cell carcinoma complicating hidradenitis suppurativa. Eur J Surg Oncol 1995;21:106–109.
  20. Dufresne RG Jr, Ratz JL, Bergfeld WF, Roenigk RK: Squamous cell carcinoma arising from the follicular occlusion triad. J Am Acad Dermatol 1996;35:475–477.
  21. Malaguarnera M, Pontillo T, Pistone G, Succi L: Squamous-cell cancer in Verneuil’s disease (hidradenitis suppurativa). Lancet 1996;348:1449.
  22. Li M, Hunt MJ, Commens CA: Hidradenitis suppurativa, Dowling-Degos disease and perianal squamous cell carcinoma. Australas J Dermatol 1997;38:209–211.
  23. Ritz JP, Runkel N, Haier J, Buhr HJ: Extent of surgery and recurrence rate of hidradenitis suppurativa. Int J Colorectal Dis 1998;13:164–168.
  24. Manolitsas T, Biankin S, Jaworski R, Wrain G: Vulval squamous cell carcinoma arising in chronic hidradenitis suppurativa. Gynecol Oncol 1999;75:285–288.
  25. Lin MT, Breiner M, Fredricks S: Marjolin’s ulcer occurring in hidradenitis suppurativa. Plast Reconstr Surg 1999;103:1541–1543.
  26. Cosman BC, O’Grady TC, Pekarske S: Verrucous carcinoma arising in hidradenitis suppurativa. Int J Colorectal Dis 2000;15:342–346.
  27. Altunay IK, Gokdemir G, Kurt A, Kayaoglu S: Hidradenitis suppurativa and squamous cell carcinoma. Dermatol Surg 2002;28:88–90.
  28. Bocchini SF, Habr-Gama A, Kiss DR, Imperiale AR, Araujo SE: Gluteal and perianal hidradenitis suppurativa: surgical treatment by wide excision. Dis Colon Rectum 2003;46:944–949.
  29. Crain VA, Gulati S, Bhat S, Milner SM: Marjolin’s ulcer in chronic hidradenitis suppurativa. Am Fam Physician 2005;71:1652–1657.
  30. Rosenzweig LB, Brett AS, Lefaivre JF, Vandersteenhoven JJ: Hidradenitis suppurativa complicated by squamous cell carcinoma and paraneoplastic neuropathy. Am J Med Sci 2005;329:150–152.
  31. Montagliani L, Monneuse O, Braye F, Barth X, Claudy A, Tissot E: Hidradenitis suppurativa and cancer. J Chir 2005;146:381–382.

    External Resources

  32. Maalouf E, Faye O, Poli F, Cosnes A, Revuz J: Carcinome épidermoïde fatal compliquant une maladie de Verneuil après traitement par infliximab. Ann Dermatol Vénéréol 2006;133:473–474.
  33. Kurokawa I, Nishimura K, Yamanaka K, Mizutani H, Tsubura A, Revuz J: Cytokeratin expression in squamous cell carcinoma arising from hidradenitis suppurativa (acne inversa). J Cutan Pathol 2007;34:675–678.
  34. MacLean GM, Coleman DJ: Three fatal cases of squamous cell carcinoma arising in chronic perineal hidradenitis suppurativa. Ann R Coll Surg Engl 2007;89:709–712.
  35. Barresi V, Vitarelli E, Barresi G: Acne inversa complicated by squamous cell carcinoma in association with diffuse malignant peritoneal mesothelioma arising in the absence of predisposing factors: a case report. J Cutan Pathol 2008;35:70–73.
  36. Ben AJ, Bouasker I, Najah H, Zribi H, Bedoui R, Guesmi F, Hani MA, Nouira R, Zoghlami A, Najah N: Squamous cell carcinoma arising in Verneuil’s disease. Tunis Med 2008;86:169–170.

    External Resources

  37. Lapins J, Ye W, Nyrén O, Emtestam L: Incidence of cancer among patients with hidradenitis suppurativa. Arch Dermatol 2001;137:730–734.
  38. Slade DEM, Powell BW, Mortimer PS: Hidradenitis suppurativa: pathogenesis and management. Br J Plast Surg 2003;56:451–461.
  39. Bassukas ID, Hundeiker M: Acne inversa (pyodermia fistulans sinifica) and smoking. J Am Acad Dermatol 1997;36:1029.
  40. Humphrey LJ, Playforth H, Leavell UW: Squamous cell carcinoma arising in hidradenitis suppurativa. Arch Dermatol 1969;100:59–62.
  41. Wortsman X, Jemec GB: Real-time compound imaging ultrasound of hidradenitis suppurativa. Dermatol Surg 2007;33:1340–1342.
  42. Wortsman X, Revuz J, Jemec GB: Lymph nodes in hidradenitis suppurativa. Dermatology 1999;198:261–264.
  43. Ross AS, Schmults CD: Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: a systematic review of the English literature. Dermatol Surg 2006;32:1309–1321.
  44. Sparks MK, Kuhlman DS, Prieto A, Callen JP: Hypercalcaemia in association with cutaneous squamous cell carcinoma. Arch Dermatol 1985;121:243–246.
  45. Alexander SR: Squamous cell carcinoma in chronic hidradenitis suppurativa: a case report. Cancer 1979;43:745–748.
  46. Jemec GB, Heidenheim M, Nielsen NH: A case control study of hidradenitis suppurativa in an STD population. Acta Derm Venereol 1996;76:482–483.
  47. Zhao X, Rasmussen S, Perry J, Kiev J: The human papillomavirus as a possible cause of squamous cell carcinoma: a case study with a review of the medical literature. Am Surg 2006;72:49–50.
  48. Gholam P, Enk A, Hartschuh W: Successful surgical management of giant condyloma acuminatum (Buschke-Löwenstein tumor) in the genitoanal region: a case report and evaluation of current therapies. Dermatology 2009;218:56–59.
  49. Iftner A, Klug SJ, Garbe C, Blum A, Stancu A, Wilczynski SP, Iftner T: The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors. Cancer Res 2003;63:7515–7519.
  50. Humbey O, Cairey-Remonnay S, Guerrini JS, Algros MP, Mougin C, Bittard H, Aubin F: Detection of the human papillomavirus and analysis of the TP53 polymorphism of exon 4 at codon 72 in penile squamous cell carcinomas. Eur J Cancer 2003;39:684–690.
  51. Krustrup D, Jensen HL, Van den Brule AJ, Frisch M: Histological characteristics of human papilloma-virus-positive and -negative invasive and in situ squamous cell tumours of the penis. Int J Exp Pathol 2009;90:182–189.
  52. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S: Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009;124:1626–1636.
  53. Flores R, Beibei L, Noelson C, Abrahamsen M, Wolf K, Lee JH, Harris RB, Giuliano AR: Correlates of human papillomavirus viral load infection site in asymptomatic men. Cancer Epidemiol Biomarkers Prev 2008;17:3573–3576.
  54. Antoniou C, Kosmadaki MG, Stratigos AJ, Katsambas AD: Genital HPV lesions and molluscum contagiosum occurring in patients receiving anti-TNF-alpha therapy. Dermatology 2008;216:364–365.
  55. Mekkes J, Bos JD: Long-term efficacy of a single course of infliximab in hidradentitis suppurativa. Br J Dermatol 2008;158:370–374.
  56. Cusack C, Buckley C: Etanercept: effective in the management of hidradenitits suppurativa. Br J Dermatol 2006;154:726–729.
  57. Moul D, Kormann NJ: Severe hidradenitis suppurativa treated with adalimumab. Arch Dermatol 2006;142:1110–1112.
  58. Blanco R, Martinez-Taboada VM, Villa I, Gonzalez-Vela MC, Fernandez-Llaca H, Agudo M, Gonzalez-Lopez MA: Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch Dermatol 2009;145:580–584.
  59. Comte C, Guilhou JJ, Guillot B, Dereure O: Rapid onset and fatal outcome of two squamous cell carcinomas of the genitalia in a patient treated with etanercept for cutaneous psoriasis. Dermatology 2008;217:284–285.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50